LODO 141
Alternative Names: LODO-141; TIR-199Latest Information Update: 28 Oct 2024
At a glance
- Originator Michigan State University; University of California Riverside School of Medicine
- Developer Ginkgo Bioworks; University of California Riverside School of Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Mantle-cell lymphoma; Multiple myeloma; Renal cell carcinoma; Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
- 28 Oct 2024 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in USA
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA